Genetic [16, 17] or pharmacological inhibition of GSDMD (e.g., by disulfiram, necrosulfonamide, dimethyl fumarate, or NU6300) [18, 19, 20, 21] reduces pyroptosis and improves survival in sepsis models, validating its therapeutic potential. The gene discussed is GSDMD; the disease is Sepsis.